Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
Globenewswire·2025-10-27 01:00Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseasesAdvances the Novartis xRNA strategy by adding a scientifically robust, muscle-directed, Antibody Oligonucleotide Conjugates (AOCs™) platform and first-in-disease pipelineExpected to unlock multi-billion-dollar opportunities with planned product launches before 2030 Raises expected 2024-2029 sales CAGR for Novartis from +5% to +6%, an ...